Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 188
- Registration Number
- NCT00526513
- Locations
- 🇪🇬
Sanofi-Aventis Administrative Office, Cairo, Egypt
APIDRA Registration Study
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT00489190
- Locations
- 🇰🇿
Sanofi-Aventis, Almaty, Kazakhstan
Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
- Conditions
- Interventions
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- The Royal Bournemouth Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT00467636
- Locations
- 🇬🇧
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 485
- Registration Number
- NCT00467376
- Locations
- 🇨🇳
Sanofi-Aventis, Beijing, China
Insulin Glulisine, Diabetes Mellitus Type 1
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT00397553
- Locations
- 🇷🇺
Sanofi-Aventis, Moscow, Russian Federation
Insulin Glargine "All to Target" Trial
- Conditions
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 588
- Registration Number
- NCT00384085
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Dose-Exposure-Response in Type 1 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2006-08-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT00368394
- Locations
- 🇩🇪
Sanofi-Aventis, Neuss, Germany
Insulin Glulisine in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT00360698
- Locations
- 🇷🇺
Sanofi-Aventis, Moscow, Russian Federation
🇬🇧Sanofi-aventis, Guildford, United Kingdom
Insulin Glulisine in Healthy Lean and Obese Subjects
- Conditions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00311077
Insulin Glulisine in Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00310297
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.